ATALAY, Selma et al. Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study. Acta Dermato-Venereologica, [S. l.], v. 100, n. 19, p. 1–7, 2020. DOI: 10.2340/00015555-3692. Disponível em: https://medicaljournalssweden.se/actadv/article/view/1863. Acesso em: 10 may. 2026.